"Be Well Clinical Studies, a medical research company, was formed to provide a venue to participate in clinical research trials that focus on conditions affecting our ability to live healthy lives. This involvement in cutting-edge research will improve the health and wellness of everyone today and into the future. Our company is driven by our desire to bring new medications to market, swiftly and effectively."

During the past decade, Be Well Clinical Studies conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Be Well Clinical Studies" #1 sponsor was "ModernaTX, Inc." with 3 trials, followed by "Pfizer" with 2 trials sponsored, "Abbott Nutrition" with 1 trials sponsored, "Bavarian Nordic" with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

According to Clinical.Site data, the most researched conditions in "Be Well Clinical Studies" are "COVID-19" (1 trials), "Gastro-Intestinal Tolerance" (1 trials), "Group B Streptococcus Infections" (1 trials), "Influenza, Human" (1 trials) and "Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention" (1 trials). Many other conditions were trialed in "Be Well Clinical Studies" in a lesser frequency.

Most popular intervention types in "Be Well Clinical Studies" are "Biological" (10 trials), "Other" (4 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "mRNA-1273.214" (2 trials), "Ad26.RSV.PreF-based Vaccine" (1 trials), "Afluria® Quadrivalent" (1 trials) and "Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Be Well Clinical Studies" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Be Well Clinical Studies". undefined are not yet recruiting, 3 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Be Well Clinical Studies, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Be Well Clinical Studies, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".